XERS - Xeris Biopharma: Checking-In On One Of My 'Top Ideas'
2024-03-30 01:28:53 ET
Summary
- Xeris Biopharma has not yet achieved cash flow breakeven and may no longer be a "Top Idea" in the Compounding Healthcare Investing Group.
- Xeris has three approved products and a strong pipeline, with potential for market penetration and revenue growth.
- Risks include competition from larger healthcare companies and the FDA approval of a generic version of one of Xeris' products, Keveyis.
It has been over a year since my last Xeris Biopharma ( XERS ) article , where I reviewed the company’s 2022 achievements including record net product revenue, driven by robust growth in our approved product portfolio. In addition, I also pointed out that company management was confident in their trajectory toward cash flow breakeven by the end of 2023. At that time, XERS was trading near $1.25 per share with a market cap of approximately $189M, I observed a notable disparity between the stock's valuation and its growth potential. As a result, I stood firm with the choice to keep XERS as a “Top Idea” in the my Seeking Alpha Investing Group and discussed my plans for 2023. Well, my plan has been a partial success by grabbing some XERS shares around $1.15 per share back in March of last year… but that was my last XERS transaction. Unfortunately, despite significant growth, the company has not hit breakeven as Keveyis deals with generics. Xeris may no longer be worthy of a “Top Idea” designation....
Xeris Biopharma: Checking-In On One Of My 'Top Ideas'